← Patent-cliff monitor small molecule TEPMETKO TEPOTINIB HYDROCHLORIDE
Loss of exclusivity March 2030 latest FDA-listed patent expiry
Company EMD Serono → See this company's full patent-cliff portfolio Drug detail Brand name TEPMETKO Active ingredient TEPOTINIB HYDROCHLORIDE Strength EQ 225MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval February 2021 Marketing status RX
Listed patents Patent Expires Type 8580781 March 2030 substance, product 8329692 October 2029 substance, product 8927540 July 2028 use U-3078 8658643 July 2028 use U-3077 9403799 July 2028 use U-3077 9062029 July 2028 product 8921357 May 2028 substance, product 9284300 April 2028 product
Regulatory exclusivity Code Expires ODE-325 February 2028 NCE February 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.